SCHEDULE 13G/A: Vanguard Group Amends Passive Stake in Pacific Biosciences, Holding 5.46% of Common Stock

The Vanguard Group has filed an Amendment No. 3 to its Schedule 13G, disclosing a 5.46% beneficial ownership stake in Pacific Biosciences of California Inc. as of March 31, 2025.

Summary

• The Vanguard Group, an investment adviser based in Malvern, PA, filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Pacific Biosciences of California Inc.
• As of March 31, 2025, The Vanguard Group beneficially owned an aggregate of 16,263,411 shares of Pacific Biosciences of California Inc. Common Stock.
• This ownership represents 5.46% of the total class of securities.
• The Vanguard Group holds sole voting power over 0 shares and shared voting power over 166,148 shares.
• The firm holds sole dispositive power over 15,869,908 shares and shared dispositive power over 393,503 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, providing no positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a routine disclosure by a large institutional investor, The Vanguard Group, regarding its passive ownership stake in Pacific Biosciences of California Inc. It reflects Vanguard's investment strategy across various public companies, rather than a specific industry trend related to Pacific Biosciences' sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a passive investment approach.

Key Dates

Keywords

Pacific Biosciences of California Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Disclosure, Investment Adviser